Immunoprophylaxis against and prevention of recurrent viral hepatitis after liver transplantation.
The reinfection of the hepatic allograft with hepatitis B virus and hepatitis C virus can have important sequelae that result in poor long-term patient and graft survival. Although a response to treatment with antiviral medications can improve these outcomes, not all patients tolerate these medications or experience viral eradication. Avoiding reinfection of the graft is the most effective means of improving the long-term outcomes for these patient populations. This review is focused on the prevention of viral hepatitis reinfection after liver transplantation.
Multi-Organ Transplant Program, Dalhousie University, Halifax, Nova Scotia, Canada.
Marie A
MA
Laryea
Kymberly D
KD
Watt
D000998:Antiviral Agents / Q000627:therapeutic use; D006509:Hepatitis B / Q000175:diagnosis / Q000517:prevention & control*; D017325:Hepatitis B Vaccines / Q000276:immunology; D006526:Hepatitis C / Q000517:prevention & control*; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use; D016031:Liver Transplantation / Q000009:adverse effects*; D012008:Recurrence; D012307:Risk Factors
D000998:Antiviral Agents; D017325:Hepatitis B Vaccines; D007136:Immunoglobulins; C045213:hepatitis B hyperimmune globulin